Lancashire and South Cumbria
Formulary
Formulary
10 Musculoskeletal and joint diseases
10-03-02 Capsaicin
| Capsaicin |
|
Formulary
|
Cream 0.025%, 0.075% Where prescribers intended to use capsaicin cream for neuropathic pain, please refer to the LSCMMG neuropathic pain guidelines.
For osteoarthritis, patients should be advised to consider self-care/OTC treatments. |
 LSCMMG: Neuropathic Pain: Primary Care Management |
|
for osteoarthritis| Capsaicin Qutenza® |
|
Formulary
|
Patch 179mg (8%) To be used as last line when all other alternative treatment options have been exhausted. |
|
LSCMMG: Qutenza (capsaicin) 179mg cutaneous patch NMR |
|
Links
- Bandolier review
- Biosimilars policy statement
- Lancashire and South Cumbria Infant Feeding Network - Diagnosis and Management of Milk Allergy and Intolerance Guideline
- LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway
- LSCMMG: Neuropathic Pain: Primary Care Management
- LSCMMG: Over the Counter Items that Should not be Routinely Prescribed in Primary Care Policy
- LSCMMG: Primary Care Constipation Guidelines
- LSCMMG: Qutenza (capsaicin) 179mg cutaneous patch NMR
- MHRA safety information on photosensivity reactions
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- NHSE: Items which should not routinely be prescribed in primary care: policy guidance
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people